Sun Pharma Gets Rights To $3.7 Bn Cholesterol Drug Market Outside US, China

Licensing deal with LIB Therapeutics covers Lerodalcibep, a once-monthly PCSK9 inhibitor, across markets excluding the US and ChinaSun Pharmaceutical Industries has signed a global licensing agreement with US-based LIB Therapeutics for Lerodalcibep, a once-monthly cholesterol-lowering drug, giving…